Core Viewpoint - Inogen reported a quarterly loss of $0.25 per share, which was better than the Zacks Consensus Estimate of a loss of $0.52, and an improvement from a loss of $0.62 per share a year ago [1][2] Financial Performance - The company achieved revenues of $82.28 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26% and showing an increase from $78.03 million in the same quarter last year [3] - Inogen has surpassed consensus EPS estimates in all four of the last quarters [2][3] Stock Performance - Inogen shares have declined approximately 22.9% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [4] - The current Zacks Rank for Inogen is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $91.8 million, and for the current fiscal year, it is -$1.41 on revenues of $352.81 million [8] - The trend of estimate revisions for Inogen is mixed, which could change following the recent earnings report [7] Industry Context - The Medical - Instruments industry, to which Inogen belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

Vishay Intertechnology (VSH) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this chipmaker would post earnings of $0.11 per share when it actually produced break-even earnings, delivering a surprise of -100%. There are no easy answers to this key question, but one reliable measure that can help investors address this is ...

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -17.39%. A quarter ago, it was expected that this company would post a loss of $0.69 per share when it actually produced a loss of $0.72, delivering a surprise of -4.35%.Over the last four quarters, the compan ...

Group 1 - Super Micro Computer (SMCI) reported quarterly earnings of $0.31 per share, exceeding the Zacks Consensus Estimate of $0.30 per share, but down from $0.67 per share a year ago, representing an earnings surprise of 3.33% [1] - The company posted revenues of $4.6 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.13%, compared to $3.85 billion in the same quarter last year [2] - Super Micro has outperformed the S&P 500, gaining about 5.5% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.61 on revenues of $6.69 billion, and for the current fiscal year, it is $2.28 on revenues of $23.16 billion [7] - The Computer-Storage Devices industry, to which Super Micro belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, indicating potential challenges ahead [8] - The estimate revisions trend for Super Micro is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting it may underperform the market in the near future [6]

Group 1 - Standard BioTools reported a quarterly loss of $0.04 per share, which is an improvement from a loss of $0.23 per share a year ago, aligning with the Zacks Consensus Estimate [1] - The company posted revenues of $40.8 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.73%, but down from $45.54 million year-over-year [2] - Standard BioTools shares have declined approximately 34.3% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] Group 2 - The earnings outlook for Standard BioTools is mixed, with current consensus EPS estimates at -$0.05 for the coming quarter and -$0.16 for the current fiscal year, with revenues expected at $38.9 million and $169.2 million respectively [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Group 1 - Arcutis Biotherapeutics reported a quarterly loss of $0.20 per share, which was better than the Zacks Consensus Estimate of a loss of $0.21, and an improvement from a loss of $0.32 per share a year ago, resulting in an earnings surprise of 4.76% [1] - The company achieved revenues of $65.85 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.26%, and showing a year-over-year increase from $49.57 million [2] - Over the last four quarters, Arcutis Biotherapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2 - The stock has increased approximately 10.6% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $72.93 million, and for the current fiscal year, it is -$0.55 on revenues of $307.74 million [7] - The Medical - Biomedical and Genetics industry, to which Arcutis Biotherapeutics belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Bioventus reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, and showing an increase from $0.07 per share a year ago, indicating a positive earnings surprise of 33.33% [1] Financial Performance - The company achieved revenues of $123.88 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.72%, although this represents a decline from $129.46 million in the same quarter last year [2] - Over the last four quarters, Bioventus has exceeded consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance - Bioventus shares have declined approximately 33.1% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.24 on revenues of $148.6 million, and for the current fiscal year, it is $0.66 on revenues of $565.01 million [7] - The estimate revisions trend for Bioventus is currently favorable, leading to a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Bioventus belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8]

Core Insights - UL Solutions Inc. reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.32 per share, and showing an increase from $0.28 per share a year ago, resulting in an earnings surprise of 15.63% [1] - The company achieved revenues of $705 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.16% and up from $670 million year-over-year [2] - UL Solutions Inc. shares have increased approximately 20.2% since the beginning of the year, contrasting with a decline of 3.9% in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.47, with projected revenues of $769.66 million, and for the current fiscal year, the EPS estimate is $1.70 on revenues of $3.02 billion [7] - The estimate revisions trend for UL Solutions Inc. is mixed, leading to a Zacks Rank of 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Business - Services industry, to which UL Solutions Inc. belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, ABM Industries, is expected to report quarterly earnings of $0.88 per share, reflecting a year-over-year change of +1.2%, with revenues anticipated to be $2.08 billion, up 2.8% from the previous year [9]

Core Viewpoint - Cipher Mining Inc. reported a quarterly loss of $0.11 per share, aligning with the Zacks Consensus Estimate, compared to earnings of $0.13 per share a year ago [1] - The company has shown mixed performance in terms of revenue and earnings estimates over the past quarters [2][6] Financial Performance - Cipher Mining's revenues for the quarter ended March 2025 were $48.96 million, missing the Zacks Consensus Estimate by 2.48%, but showing an increase from $48.14 million year-over-year [2] - The company has surpassed consensus revenue estimates only once in the last four quarters [2] Stock Performance - Cipher Mining shares have declined approximately 35.8% since the beginning of the year, contrasting with the S&P 500's decline of 3.9% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $51.68 million, and for the current fiscal year, it is -$0.39 on revenues of $255.36 million [7] - The trend of estimate revisions for Cipher Mining is mixed, which may change following the recent earnings report [6] Industry Context - The Technology Services industry, to which Cipher Mining belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Performance - SOPHiA GENETICS reported a quarterly loss of $0.26 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.21, representing an earnings surprise of -23.81% [1] - The company posted revenues of $17.78 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 7.30% and showing an increase from $15.78 million in the same quarter last year [2] - Over the last four quarters, SOPHiA GENETICS has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Market Outlook - SOPHiA GENETICS shares have increased by approximately 2.3% since the beginning of the year, contrasting with the S&P 500's decline of -3.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.20 on revenues of $17.85 million, and for the current fiscal year, it is -$0.80 on revenues of $74.18 million [7] Industry Context - The Medical Info Systems industry, to which SOPHiA GENETICS belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for SOPHiA GENETICS is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]